In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

GlaxoSmithKline, and Novartis. According to TipRanks, Welford has an average return of 4.4% and a 52.89% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy ...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

It’s been a weekend of love-ins for Big Pharma: first, there was the revelation that European (Swedish-British) firm AstraZeneca and American firm Pfizer had been in talks. Now, Novartis (Swiss) and ...

And finally, its high-profile China president, Leon Wang, has been detained by authorities over the past week. AstraZeneca has told investors that it does not have clear visibility on the reasons.

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...

1 Day. 20 Pharma Senior Speakers From GSK, Pfizer, AstraZeneca & More Explore Impactful, Value-Adding & Engaging Pharma Comms Strategies! Book 4 For The Price Of 3! Limited Discounted Places ...